Mylan receives final FDA OK for Alprazolam Extended-release Tablets

By Lisa Kerner

Erie, Pa., Jan. 27 - Mylan Laboratories Inc. said it has received final approval from the Food and Drug Administration for its abbreviated New Drug Application for Alprazolam Extended-release Tablets, 0.5 mg, 1mg, 2 mg and 3 mg.

Alprazolam Extended-release Tablets are the AB-rated generic equivalent of Pharmacia's and Upjohn's Xanax XR Tablets, according to a company news release.

Mylan said its product will begin shipping immediately.

Mylan Laboratories and its subsidiaries develop, license, manufacture, market and distribute generic and proprietary products. The company is based in Canonsburg, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.